Zheng-kai Feng
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: February 10, 2026
Pedicled Inferior Turbinate-Nasal Floor and Septal Mucoperiosteal Flap Resurfacing for PRNN.
Journal: The Laryngoscope
Published: November 05, 2025
TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial.
Journal: Med (New York, N.Y.)
Published: April 17, 2025
Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma.
Journal: Annals of surgical oncology
Published: January 20, 2025
Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 23, 2024
Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
Journal: Oral oncology
Published: October 21, 2024
Nasopharyngeal Endoscopic Submucosal Dissection (NESD) for Stage I Nasopharyngeal Carcinoma.
Journal: The Laryngoscope
Published: August 28, 2024
Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
Journal: Oral oncology
Published: June 30, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Journal: Cell reports. Medicine
Published: July 23, 2023
A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.
Journal: Head & neck
Published: May 11, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: January 12, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026